Statistiche di base
| LEI | 254900CU6T74V18Y1W18 |
| CIK | 1434647 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zevra Therapeutics Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2025 |
Exhibit 99.1 Zevra Reports Second Quarter 2025 Financial Results and Corporate Update Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency f |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 00 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 29, 2025 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2025 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 13, 2025 |
Asset Purchase Agreement dated February 26, 2025. Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 26, 2025 (the “Effective Date”), by and between [***] (“Buyer”), Zevra Therapeutics, Inc., a corporation organized under the laws of Delaware (“Seller”), and solely with respect to Section 10.01(c), Zevra Denmark A/S, a Danish public limited company (“Zevr |
|
| May 13, 2025 |
Exhibit 99.1 Zevra Reports First Quarter 2025 Financial Results and Corporate Update Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company’s commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra The |
|
| May 13, 2025 |
Tenth Amended and Restated Non-Employee Director Compensation Policy effective February 15, 2025. Exhibit 10.1 Zevra Therapeutics, Inc. Tenth Amended and Restated Non-Employee Director Compensation Policy Effective: February 15, 2025 Each member of the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) who is not also an employee of the Company or any subsidiary of the Company shall be entitled to the following compensation for service on the Board and its committees: |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A/A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. 2) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 21, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A/A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 7, 2025 |
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million EX-99.1 Exhibit 99.1 Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million Celebration, FL – Apr. 7, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2025 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 12, 2025 As filed with the Securities and Exchange Commission on March 12, 2025 Registration No. |
|
| March 13, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated 201 |
|
| March 12, 2025 |
Zevra Therapeutics, Inc. Amended and Restated Insider Trading and Window Period Policy. Exhibit 19 ZEVRA THERAPEUTICS, INC. Amended and Restated INSIDER TRADING AND WINDOW PERIOD POLICY I. INTRODUCTION This policy determines acceptable transactions in the securities of Zevra Therapeutics, INC. (the “Company”) by our employees, officers, directors and consultants. During the course of your relationship with the Company, you may receive important information that is not yet publicly av |
|
| March 12, 2025 |
Employment Agreement by and between the Registrant and Adrian Quartel, dated as of January 3, 2024. Exhibit 10.13 ZEVRA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT ADRIAN QUARTEL EFFECTIVE AS OF JANUARY 3, 2024 ZEVRA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT ("Agreement') is made and entered into effective as of JANUARY 3, 2024, by and between ZEVRA THERAPEUTICS, INC., a Delaware corporation (the "Company"), including its affiliates, parent, subsidiaries, successors, and assi |
|
| March 12, 2025 |
Employment Agreement by and between the Registrant and Joshua Schafer, dated as of January 6, 2023. Exhibit 10.14 KEMPHARM, INC. EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into effective as of the 6th day of January 2023, by and between KEMPHARM, INC. a Delaware corporation (the "Company") and JOSHUA SCHAFER ("Executive") (each being a "Party" hereto and together constituting the "Parties"). WHEREAS, Company desires to employ Executive an |
|
| March 12, 2025 |
Exhibit 10.16 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of May 7, 2024, is entered into by and between Zevra Therapeutics, Inc. (the “Company”) and Neil F. McFarlane (“Executive”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Employment Agreement (as |
|
| March 12, 2025 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zevra Therapeutics, Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our common stock, par value $0.0001 per share, or common stock. The following description of our capital stock is a |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2025 |
Exhibit 99.1 Zevra Reports Fourth Quarter and Full Year 2024 Financial Results FY 2024 net revenue of $23.6 million, driven by record product net revenue of $10.2 million during Q4 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Mar. 11, 2025 - Zevra Therapeutics, Inc. ( |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2025 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2025 |
Exhibit 99.1 Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million Celebration, FL – Feb. 27, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement |
|
| February 12, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 6, 2024 |
Zevra Therapeutics Announces Organizational Changes Exhibit 99.1 Zevra Therapeutics Announces Organizational Changes Celebration, Fla – Dec. 6, 2024 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. The co |
|
| November 22, 2024 |
Exhibit 99.1 Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssistTM, Zevra’s comprehensive patient support program, in place to address access barriers CELEBRATION, Fla., Nov. 2 |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 21, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State |
|
| November 14, 2024 |
ZVRA / Zevra Therapeutics, Inc. / Woodline Partners LP - ZEVRA THERAPEUTICS, INC. Passive Investment SC 13G 1 p24-3057sc13g.htm ZEVRA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Zevra Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 488445206 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Che |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 12, 2024 |
Exhibit 99.1 Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ends quarter with cash, cash equivalents and investments of $95.5 million Company to host conferenc |
|
| September 20, 2024 |
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adults and pediatric pati |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 20, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (Stat |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra Ther |
|
| August 14, 2024 |
Employment Agreement by and between the Registrant and Rahsaan Thompson, dated as of June 21, 2024. Zevra Therapeutics, Inc. Employment Agreement Rahsaan Thompson Effective as of June 20, 2024 Zevra Therapeutics, Inc. Employment Agreement This Employment Agreement (“Agreement”) is made and entered into on June 20, 2024, by and between Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), including its affiliates, parent, subsidiaries, successors, and assigns and Rahsaan Thompson (“Ex |
|
| August 13, 2024 |
Exhibit 99.1 Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro-forma June 30, 2024, cash, cash equivalents, investments and net proceeds from underwritten public offering total $113.8 million following th |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279941 9,230,770 Shares Common Stock We are offering 9,230,770 shares of our common stock. Our common stock is traded on the Nasdaq Global Select Market under the symbol “ZVRA.” On August 7, 2024, the last reported sale price of our common stock was $7.24 per share. Investing in our common stock involves a high degree of risk. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2024 |
Exhibit 1.1 ZEVRA THERAPEUTICS, INC. 9,230,770 Shares of Common Stock (par value $0.0001 per share) Underwriting Agreement August 8, 2024 Cantor Fitzgerald & Co. William Blair & Company, L.L.C. As Representatives of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicag |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279941 The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or |
|
| August 5, 2024 |
Exhibit 99.1 FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C PDUFA Action Date for the Arimoclomol NDA is September 21, 2024 CELEBRATION, Fla., August 2, 2024 (GLOBE NEWSWIRE) - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 12, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commission |
|
| July 12, 2024 |
424B2 Table of Contents Prospectus Supplement (to Prospectus dated June 13, 2024) Filed Pursuant to Rule 424(b)(2) Registration No. |
|
| July 12, 2024 |
Zevra Therapeutics, Inc. $75,000,000 Common Stock EQUITY DISTRIBUTION AGREEMENT Dated: July 12, 2024 TABLE OF CONTENTS Page SECTION 1. Description of Securities. 1 SECTION 2. Placements. 2 SECTION 3. Sale of Placement Securities by the Placement Agent. 3 SECTION 4. Suspension of Sales 4 SECTION 5. Representations and Warranties. 4 SECTION 6. Sale and Delivery to the Placement Agent; Settlement. 20 |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or O |
|
| July 9, 2024 |
Exhibit 99.1 Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C Meeting with the recently formed GeMDAC set for August 2, 2024 CELEBRATION, Fla., July 9, 2024 (GLOBE NEWSWIRE) - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and Drug Adminis |
|
| June 10, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 June 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed June 4, 2024 Registration No. 333-279941 Ladies and Gentlemen: In ac |
|
| June 4, 2024 |
Form of Indenture between the Registrant and one or more trustees to be named. EX-4.6 EXHIBIT 4.6 ZEVRA THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| June 4, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 ZEVRA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ZEVRA THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ZEVRA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and e |
|
| June 4, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zevra Therapeutics, Inc. |
|
| June 4, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 ZEVRA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ZEVRA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ZEVRA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi |
|
| June 4, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 ZEVRA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ZEVRA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ZEVRA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] orga |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 4, 2024 Registration No. |
|
| June 3, 2024 |
Exhibit 99.1 Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on pharmacokinetics of morning and nighttime doses of KP1077 |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or O |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra The |
|
| May 9, 2024 |
Exhibit 10.1 Pursuant to Item 601(b)(2)(ii), certain identified information marked with [***] has been excluded from this exhibit because it is both not material and is the type that the registrant customarily and actually treats as private or confidential. FLORIDA DOCUMENTARY STAMP TAX REQUIRED BY LAW IN THE AMOUNT OF $2,450.00 HAS BEEN PAID OR WILL BE PAID DIRECTLY TO THE DEPARTMENT OF REVENUE. |
|
| May 8, 2024 |
Exhibit 99.1 Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with PDUFA date of September 21, 2024 Reported positive topline results from KP1077 Phase 2 Trial in idiopathic hypersomnia, with full da |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2024 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2024 |
2,269,721 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276856 PROSPECTUS 2,269,721 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 2,269,721 shares of our common stock, $0.0001 par value per share, that were issued to the selling stockholders pursuant to the loan purchase ag |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or |
|
| April 8, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 S-3/A As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 4, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 April 4, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tim Buchmiller Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 2, 2024 Registration No. 333-276856 Ladies and Gentlemen: |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 2, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated 202 |
|
| April 2, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated 201 |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 97.1 ZEVRA THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Zevra Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact |
|
| April 1, 2024 |
2023 Employment Inducement Award Plan and forms of award agreements thereunder. Exhibit 10.7.8 Zevra Therapeutics, Inc. 2023 Employment Inducement Award Plan (As Amended and Restated February 22, 2024) 1. General. (a) Eligible Award Recipients. Eligible Individuals are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights (iii) Restricted Stock Awards, (iv) Rest |
|
| April 1, 2024 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zevra Therapeutics, Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our common stock, par value $0.0001 per share, or common stock. The following description of our capital stock is a |
|
| April 1, 2024 |
Exhibit 21.1 Subsidiaries of Zevra Therapeutics, Inc. The following companies are direct or indirect wholly owned subsidiaries of Zevra Therapeutics, Inc.: Name Jurisdiction Acer Therapeutics Inc. United States |
|
| April 1, 2024 |
Exhibit 10.31 FIRST AMENDMENT TO BRIDGE LOAN AGREEMENT This First Amendment to Bridge Loan Agreement (this “Amendment”), dated as of October 31, 2023, is by and between ACER THERAPEUTICS INC., a Delaware corporation (the “Borrower”), and ZEVRA THERAPEUTICS, INC., a Delaware corporation (the “Lender”). RECITALS A. The Borrower and the Lender have entered into that certain Bridge Loan Agreement, dat |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
Exhibit 99.1 Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET Celebration, FL – M |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or |
|
| March 27, 2024 |
Exhibit 99.1 Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study Celebration, Fla. – March 26, 2024 (GLOBE NEWSWIRE) – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disea |
|
| March 6, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 March 6, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tim Buchmiller Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 2, 2024 Registration No. 333-276856 Ladies and Gentlemen: |
|
| March 5, 2024 |
March 2024 Investor Presentation Exhibit 99.1 |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 5, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State or |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 4, 2024 |
Exhibit 99.1 Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is September 21, 2024 CELEBRATION, Fla., March 4, 2024 (GLOBE NEWSWIRE) - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today ann |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K -12-31 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or |
|
| February 28, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ZEVRA THERAPEUTICS, INC. February 22, 2024 ARTICLE I OFFICES Section 1. Registered Office. The registered office and the name of the registered agent shall be fixed in the corporation’s certificate of incorporation, as the same may be amended from time to time. Section 2. Other Offices. The corporation shall also have and maintain an office or principal p |
|
| February 14, 2024 |
KMPH / Zevra Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZEVRA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 488445206 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tim Buchmiller Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 2, 2024 Registration No. 333-276856 Ladies and G |
|
| February 14, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tim Buchmiller Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 2, 2024 Registration No. 333-276856 Ladies and G |
|
| February 12, 2024 |
Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 February 12, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tim Buchmiller Re: Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 2, 2024 Registration No. 333-276856 Ladies and Gentlem |
|
| February 5, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) ZEVRA THERAPEUTICS, INC. |
|
| February 5, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 5, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On November 17, 2023 (the “Closing Date”), Zevra Therapeutics, Inc., a Delaware corporation (“Zevra” or the “Company”) completed the previously announced acquisition of Acer Therapeutics Inc., a Delaware corporation (“Acer”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated August 30, 2023, by and |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2024 (November 20, 2023) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 23, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 8, 2024 |
Exhibit 99.1 Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C Arimoclomol NDA has been assigned a PDUFA action date of June 21, 2024 CELEBRATION, Fla., January 8, 2024 (GLOBE NEWSWIRE) - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that the U.S. |
|
| January 8, 2024 |
Corporate Presentation dated January 2024. Exhibit 99.2 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State o |
|
| December 27, 2023 |
Exhibit 99.1 Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration Celebration, FL – December 27, 2023 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pi |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2023 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (Commission File (I.R.S. Employer Identification (State |
|
| November 22, 2023 |
Table of Contents PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commiss |
|
| November 20, 2023 |
EX-99.1 Exhibit 99.1 Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company Acquisition includes OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra into commercial stage, diversifying its revenue and providing scale Settlement of Acer’s warrant obligations through direct transaction with a healthca |
|
| November 20, 2023 |
EX-4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ZEVRA THERAPEUTICS, INC. Warrant Shares: 1,382,489 Issue Date: November 22, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| November 20, 2023 |
EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 20, 2023, between Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). To the extent there is only one |
|
| November 20, 2023 |
EX-10.1 Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT by and between ZEVRA THERAPEUTICS, INC. and COMPUTERSHARE TRUST COMPANY, N.A. and COMPUTERSHARE INC., collectively, as Rights Agent Dated as of November 17, 2023 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 Definitions 1 ARTICLE 2 CONTINGENT VALUE RIGHTS 6 SECTION 2.1 CVRs; Holders of C |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra |
|
| November 7, 2023 |
Exhibit 99.1 Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra’s revenue with FDA-approved OLPRUVA® for urea cycle disorders (UCDs) Net revenue of $2.9M for Q3 2023 Ended Q3 2023 with $83.4M in cash, ca |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2023 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 30, 2023 |
Exhibit 99.1 ACER THERAPEUTICS INC. SUPPLEMENT TO PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To be held on November 8, 2023 October 30, 2023 Explanatory Note As previously disclosed, on August 30, 2023, Acer Therapeutics Inc. (“Acer” or the “Company”), Zevra Therapeutics, Inc., a Delaware corporation (“Zevra”), and Aspen Z Merger Sub, Inc., a Delaware corporation and a direct wholly-o |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commissi |
|
| October 30, 2023 |
Exhibit 99.1 ACER THERAPEUTICS INC. SUPPLEMENT TO PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To be held on November 8, 2023 October 30, 2023 Explanatory Note As previously disclosed, on August 30, 2023, Acer Therapeutics Inc. (“Acer” or the “Company”), Zevra Therapeutics, Inc., a Delaware corporation (“Zevra”), and Aspen Z Merger Sub, Inc., a Delaware corporation and a direct wholly-o |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commissi |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organiza |
|
| October 10, 2023 |
Exhibit 10.1 Zevra Therapeutics, Inc. Executive Employment Agreement This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of the day of October 2023, by and between ZEVRA THERAPEUTICS, INC., a Delaware corporation (the “Company”) and NEIL F. MCFARLANE (“Executive”) (each being a “Party” hereto and together constituting the “Parties”). Whereas, Company desires to |
|
| October 10, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274758 ACER THERAPEUTICS INC. One Gateway Center, Suite 356 300 Washington Street Newton, Massachusetts 02458 October 10, 2023 PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANT To the Stockholders of Acer Therapeutics Inc.: You are cordially invited to attend a special meeting of stockholders (the “Acer Special Meeting”) of Acer The |
|
| October 6, 2023 |
October 6, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Zevra Therapeutics, Inc. Registration Statement on Form S-4 Filed September 28, 2023 (Commission File No. 333-274758) Dear Sir or Madam: In accordance with Rule 461 under the Securities Act of 1933, as amended, Zevra Therapeutics, Inc. (the “Company”) hereby requests |
|
| October 6, 2023 |
Consent of William Blair & Company L.L.C.† Exhibit 99.2 CONSENT OF WILLIAM BLAIR & COMPANY, L.L.C. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Acer Therapeutics Inc. (the “Company”) as an Appendix to the proxy statement/prospectus relating to the proposed acquisition of the Company by Zevra Therapeutics, Inc. contained in the Registration Statement on Form S-4, as filed with the Securities and Exch |
|
| October 6, 2023 |
As filed with the Securities and Exchange Commission on October 6, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 6, 2023 Registration No. |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 S-4 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) Zevra Therapeutics, Inc. |
|
| September 29, 2023 |
Consent of William Blair & Company L.L.C.† Exhibit 99.2 CONSENT OF WILLIAM BLAIR & COMPANY, L.L.C. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Acer Therapeutics Inc. (the “Company”) as an Appendix to the proxy statement/prospectus relating to the proposed acquisition of the Company by Zevra Therapeutics, Inc. contained in the Registration Statement on Form S-4, as filed with the Securities and Exch |
|
| September 29, 2023 |
Form of Acer Therapeutics Inc. proxy card.** Exhibit 99.1 Exhibit 99.1 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK *** EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail ACER THERAPEUTICS INC. As a stockholder of Acer Therapeutics Inc., you have the option of votingyour shares electronically through the Internet, eliminating the need to return the proxy card. Your electronic vote authorizes the named proxies to |
|
| August 31, 2023 |
EX-10.5 Exhibit 10.5 IN ACCORDANCE WITH ITEM 601(A)(5) OF REGULATION S-K, ZEVRA THERAPEUTICS, INC. HAS OMITTED CERTAIN EXHIBITS TO THIS AGREEMENT, MARKED BY [*****], BECAUSE ZEVRA THERAPEUTICS, INC. HAS DETERMINED THAT SUCH INFORMATION (I) DOES NOT CONTAIN INFORMATION MATERIAL TO AN INVESTMENT OR VOTING DECISION AND (II) IS NOT OTHERWISE DISCLOSED IN THIS AGREEMENT OR KEMPHARM, INC.’S OTHER SEC FI |
|
| August 31, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commi |
|
| August 31, 2023 |
EX-10.1 Exhibit 10.1 BRIDGE LOAN AGREEMENT THIS AGREEMENT is dated effective August 30, 2023. AMONG: ACER THERAPEUTICS INC., a Delaware corporation One Gateway Center, Suite 356 Newton, MA 02458 Attention: Don Joseph, CLO Email: [email protected] (the “Borrower”) AND: ZEVRA THERAPEUTICS, INC., a Delaware corporation 1180 Celebration Blvd., Suite 103 Celebration, FL 34747 Attention: LaDuane Clifto |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commissio |
|
| August 31, 2023 |
Exhibit 99.1 Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVATM, recently approved for the treatment of urea cycle d |
|
| August 31, 2023 |
Filed by Zevra Therapeutics, Inc. Exhibit 99.1 Filed by Zevra Therapeutics, Inc. Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Companies: Zevra Therapeutics, Inc. and Acer Therapeutics Inc. Commission File No.: 001-36913 Zevra Therapeutics, Inc. distributed the following communication to employees of Acer Therapeutics Inc. The following was first used on August 31, 2023. To: Acer all staff F |
|
| August 31, 2023 |
Communication to Employees of Acer Therapeutics Inc., dated August 31, 2023 Exhibit 99.1 Filed by Zevra Therapeutics, Inc. Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Companies: Zevra Therapeutics, Inc. and Acer Therapeutics Inc. Commission File No.: 001-36913 Zevra Therapeutics, Inc. distributed the following communication to employees of Acer Therapeutics Inc. The following was first used on August 31, 2023. To: Acer all staff F |
|
| August 31, 2023 |
EX-10.3 Exhibit 10.3 IN ACCORDANCE WITH ITEM 601(A)(5) OF REGULATION S-K, ZEVRA THERAPEUTICS, INC. HAS OMITTED CERTAIN EXHIBITS TO THIS AGREEMENT, MARKED BY [*****], BECAUSE ZEVRA THERAPEUTICS, INC. HAS DETERMINED THAT SUCH INFORMATION (I) DOES NOT CONTAIN INFORMATION MATERIAL TO AN INVESTMENT OR VOTING DECISION AND (II) IS NOT OTHERWISE DISCLOSED IN THIS AGREEMENT OR KEMPHARM, INC.’S OTHER SEC FI |
|
| August 31, 2023 |
EX-10.4 Exhibit 10.4 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 30, 2023, is entered into by and between (i) Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), and (ii) each of the Persons listed on Schedule A attached hereto (the “Schedule of Sellers”) (each, together with its permitted assigns, a “Selle |
|
| August 31, 2023 |
EX-99.2 Zevra Investor Call: Acer Acquisition August 31, 2023 Exhibit 99.2 Cautionary Note Regarding Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation an |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commissio |
|
| August 31, 2023 |
EX-10.2 Exhibit 10.2 IN ACCORDANCE WITH ITEM 601(A)(5) OF REGULATION S-K, ZEVRA THERAPEUTICS, INC. HAS OMITTED CERTAIN EXHIBITS TO THIS AGREEMENT, MARKED BY [*****], BECAUSE ZEVRA THERAPEUTICS, INC. HAS DETERMINED THAT SUCH INFORMATION (I) DOES NOT CONTAIN INFORMATION MATERIAL TO AN INVESTMENT OR VOTING DECISION AND (II) IS NOT OTHERWISE DISCLOSED IN THIS AGREEMENT OR KEMPHARM, INC.’S OTHER SEC FI |
|
| August 31, 2023 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among ZEVRA THERAPEUTICS, INC. ASPEN Z MERGER SUB, INC., and ACER THERAPEUTICS INC. Dated as of August 30, 2023 TABLE OF CONTENTS ARTICLE I THE MERGER 1 SECTION 1.1 The Merger 1 SECTION 1.2 Closing 1 SECTION 1.3 Effective Time 1 SECTION 1.4 Effects of the Merger 3 SECTION 1.5 Certificate of Incorporation; Bylaws 3 SECTION 1.6 Direct |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2023 |
Ninth Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Zevra Therapeutics, Inc. Ninth Amended and Restated Non-Employee Director Compensation Policy Effective: May 3, 2023 Each member of the board of director (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) who is not also an employee of the Company or any subsidiary of the Company shall be entitled to the following compensation for service on the Board and its committees: Cash C |
|
| August 14, 2023 |
Presentation dated August 14, 2023. Exhibit 99.2 |
|
| August 14, 2023 |
Exhibit 99.1 Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million milestone payment earned under the AZSTARYS® license agreement Ended Q2 2023 with $87.4 million in cash, c |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2023 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 Zevra Therapeu |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2023 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2023 |
Exhibit 10.1 May 13, 2023 Re: Agreement regarding Employment Terms Dear Christal: This letter confirms the agreement between you and Zevra Therapeutics, Inc., f/k/a KemPharm, Inc. (the “Company”) to modify certain terms of your employment during your period of service as interim Chief Executive Officer and President of the Company. Reference is made to the Employment Agreement, dated as of May 30, |
|
| May 15, 2023 |
Exhibit 99.1 Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results Christal Mickle, Co-Founder and Chief Development Officer, appointed to serve as interim President and CEO effective June 1, 2023 Conference call and live audio webcast with slide presentation scheduled for today, May 15, 2023, 4:30 p.m. ET Celebration, FL – May 15, 2023 – Zevra Therapeutics, Inc. (N |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2023 Zevra Therapeutics, Inc (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 Zevra Therape |
|
| May 15, 2023 |
Presentation dated May 15, 2023. Exhibit 99.2 |
|
| May 8, 2023 |
Exhibit 10.1 May 6, 2023 Richard Pascoe R*********@*****.com Re: Transition Agreement Dear Richard: This letter sets forth the terms of the mutual agreement (the “Agreement”) between you and Zevra Therapeutics, Inc., formerly KemPharm, Inc., (the “Company”) regarding your employment transition. 1. Transition Period and Services. As we discussed, you have resigned and the Company has accepted your |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2023 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organizat |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 29, 2023 |
DEFA14A 1 zvra20230329defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate |
|
| March 29, 2023 |
DEFA14A 1 zvra20230327bdefa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriat |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organizat |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 7, 2023 |
Amended and Restated Non-Employee Director Compensation Policy Attachment #1 KemPharm, Inc. Eighth Amended and Restated Non-Employee Director Compensation Policy Effective: February 15, 2023 Each member of the board of director (the “Board”) of KemPharm, Inc. (the “Company”) who is not also an employee of the Company or any subsidiary of the Company shall be entitled to the following compensation for service on the Board and its committees: Cash Compensation |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No. |
|
| March 7, 2023 |
Exhibit 99.1 Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET Newly rebranded Zevra Therapeutics well positioned to become a commercially focused rare disease company Arimoclomol NDA resubmission on track to be filed as early as Q3 20 |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 7, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated 201 |
|
| March 7, 2023 |
Presentation dated March 7, 2023. Exhibit 99.2 |
|
| March 7, 2023 |
2023 Employment Inducement Award Plan and forms of award agreements thereunder. Exhibit 10.7.8 ZEVRA THERAPEUTICS, INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 6, 2023 1. General. (a) Eligible Award Recipients. Eligible Individuals are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights (iii) Restricted Stock Awards, (i |
|
| March 7, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2023 Employment Induceme |
|
| March 7, 2023 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zevra Therapeutics, Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our common stock, par value $0.0001 per share, or common stock. The following description of our capital stock is a |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 6, 2023 |
CORRESP 1 filename1.htm VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers Acquisitions 100 F Street, N.E. Washington, D.C. 20549-6010 March 6, 2023 Attention: Michael Killoy Christina Chalk Re: Zevra Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 27, 2023 File No. 001-36913 Dear Mr. Killoy and Ms. Chalk: We respectful |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organi |
|
| February 27, 2023 |
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy Exhibit 99.1 Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy CELEBRATION, FL, February 27, 2023 – Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 An |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 24, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ZEVRA THERAPEUTICS, INC. (a Delaware Corporation) February 21, 2023 ZEVRA THERAPEUTICS, INC. Amended and Restated Bylaws ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of The Corporation Trust Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, |
|
| February 24, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KEMPHARM, INC. KemPharm, Inc. (hereinafter called the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. That the name of this corporation is KemPharm, Inc., and that this corporation was originall |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION -12-31 WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Zevra Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or |
|
| January 25, 2023 |
KemPharm Issues Letter to Shareholders Exhibit 99.1 KemPharm Issues Letter to Shareholders Celebration, Fla. – January 24, 2023 – KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that Richard W. Pascoe |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 KemPharm, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organization) (Co |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 KemPharm, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organization) (Co |
|
| January 9, 2023 |
Exhibit 10.1 KemPharm, Inc. First Amendment to Executive Employment Agreement This First Amendment to Executive Employment Agreement (this “First Amendment”) is entered into this 6th day of January, 2023 (the “Effective Date”), by and between Richard Pascoe (the “Executive”) and KemPharm, Inc. (the “Company”) (each being a “Party” hereto and together constituting the “Parties”). WHEREAS, the Compa |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 KemPharm, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36913 20-5894398 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 9, 2023 |
Exhibit 10.3 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Consulting Agreement This Consulting Agreement (the “Agreement”) by and between KemPharm, Inc. (“Client”) and Travis Mickle (“Consultant”) and is effective |
|
| January 9, 2023 |
Exhibit 10.2 January 4, 2023 (as modified on January 5, 2023) Travis Mickle [email protected] Re: Transition Agreement Dear Travis: This letter sets forth the terms of the mutual agreement (the “Agreement”) between you and KemPharm, Inc. (the “Company”) regarding your employment transition. 1. Transition Period and Services. As we discussed, you have resigned and the Company has accepted your r |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 9, 2022 |
EX-99.1 2 ex420031.htm EXHIBIT 99.1 Exhibit 99.1 KemPharm Reports Third Quarter 2022 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET ● Significant activities underway for preparation of the arimoclomol NDA resubmission ● Advancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022 ● Tota |
|
| November 9, 2022 |
Presentation dated November 9, 2022. EX-99.2 3 ex420032.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. |
|
| August 11, 2022 |
Presentation dated August 11, 2022. EX-99.2 3 ex382571.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| August 11, 2022 |
Exhibit 99.1 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.?s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS? ? Acquired substantially all the assets and operations of Orphazyme A/ |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 17, 2022 |
Letter from RSM US LLP dated June 17, 2022. Exhibit 16.1 June 17, 2022 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read KemPharm, Inc?s statements included under Item 4.01(a) of its Form 8-K filed on June 17, 2022 and we agree with such statements concerning our firm. /s/ RSM US LLP |
|
| June 17, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 1, 2022 |
Exhibit 10.1 Execution Version REVOLVING LOAN AGREEMENT THIS REVOLVING LOAN AGREEMENT (?Loan Agreement? or ?Agreement?) is made this 31st day of May, 2022 (?Effective Date?), by and among KEMPHARM, INC., a corporation existing under the laws of the State of Delaware with its principal place of business at 1180 Celebration Blvd., Suite 103, Celebration, Florida 34747 (?Borrower?), AMERIS BANK, with |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 16, 2022 |
Exhibit 99.1 KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC |
|
| May 16, 2022 |
Exhibit 10.1 Asset Purchase Agreement regarding certain assets in Orphazyme A/S in restructuring Gorrissen Federspiel Page 2 This Asset Purchase Agreement (the ?Agreement?) is on this day entered into between: Seller: Orphazyme A/S in restructuring, CVR no. 32 26 63 55, a company incorporated and registered under the laws of Denmark having its registered address at Ole Maal?es Vej 3, 2200 K?benhav |
|
| May 16, 2022 |
Exhibit 99.2 Arimoclomol Acquisition Call May 16, 2022 1 1 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current f |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 12, 2022 |
Exhibit 99.1 KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET ? Filed Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) for KP1077, a serdexmethylphenidate (SDX)-based product candidate for idiopathic hypersomnia (IH) o I |
|
| May 12, 2022 |
Seventh Amended and Restated Non-Employee Director Compensation Policy. EXHIBIT 10.1 KemPharm, Inc. Seventh Amended and Restated Non-Employee Director Compensation Policy Effective: February 1, 2022 Each member of the board of directors (the ?Board?) of KemPharm, Inc. (the ?Company?) who is not also an employee of the Company or any subsidiary of the Company shall be entitled to the following compensation for service on the Board and its committees: Cash Compensation |
|
| May 12, 2022 |
DEFA14A 1 kmph20220511defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate |
|
| May 12, 2022 |
Presentation dated May 12, 2022. Exhibit 99.2 |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 31, 2022 |
EX-4.5 2 ex321306.htm EXHIBIT 4.5 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 KemPharm, Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our common stock, par value $0.0001 per share, or common stock. The following description of |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Chart |
|
| March 30, 2022 |
Exhibit 99.1 KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights ? Announced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and neurodegenerative cond |
|
| March 30, 2022 |
Presentation dated March 30, 2022. Exhibit 99.2 |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2022 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-36913 20-5894398 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 21, 2022 |
Exhibit 99.1 KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep disorders Upcoming anticipated development milestones for KP1077 include: IND filing |
